eli lilly and company retatrutide A Study of (LY3437943) in Participants With Obesity Cardiovascular Disease (TRIUMPH-3) Lilly's triple agonist, retatrutide, delivered

Always help patients understand their options clearly, so they can make informed decisions about their care and cost

And a growing set of studies suggests they have a constellation of other health benefits, too

Given that GLP-1s carry a black box warning for thyroid tumors and additional warnings for pancreatitis and kidney problems, the lack of consistent baseline labs feels risky

What Retatrutide Is and Why Access Is Limited Retatrutide is being studied as a triple receptor agonist

Lubberding AF, et al

What sets Mounjaro apart is its unique ability to target two hormones critical for blood sugar regulation and metabolism: 1